RxSight (RXST) versus Its Peers Head-To-Head Review

RxSight (NASDAQ:RXSTGet Free Report) is one of 168 publicly-traded companies in the “Medical Devices” industry, but how does it weigh in compared to its rivals? We will compare RxSight to related companies based on the strength of its analyst recommendations, institutional ownership, risk, dividends, earnings, valuation and profitability.

Volatility & Risk

RxSight has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, RxSight’s rivals have a beta of 0.74, meaning that their average stock price is 26% less volatile than the S&P 500.

Institutional and Insider Ownership

66.5% of RxSight shares are owned by institutional investors. Comparatively, 31.8% of shares of all “Medical Devices” companies are owned by institutional investors. 21.1% of RxSight shares are owned by insiders. Comparatively, 20.9% of shares of all “Medical Devices” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares RxSight and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
RxSight $67.00 million -$66.76 million -14.91
RxSight Competitors $865.85 million $16.74 million 47.31

RxSight’s rivals have higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


This table compares RxSight and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
RxSight -88.72% -48.72% -33.79%
RxSight Competitors -487.25% -218.37% -29.55%

Analyst Ratings

This is a breakdown of recent ratings for RxSight and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RxSight 0 1 4 0 2.80
RxSight Competitors 455 1965 3229 132 2.53

RxSight currently has a consensus price target of $30.50, suggesting a potential upside of 2.76%. As a group, “Medical Devices” companies have a potential upside of 68.06%. Given RxSight’s rivals higher possible upside, analysts plainly believe RxSight has less favorable growth aspects than its rivals.


RxSight rivals beat RxSight on 7 of the 13 factors compared.

About RxSight

(Get Free Report)

RxSight, Inc., an ophthalmic medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.